MV 9411

Drug Profile

MV 9411

Alternative Names: MV9411

Latest Information Update: 29 Mar 2011

Price : $50

At a glance

  • Originator Miravant Medical Technologies
  • Class Skin disorder therapies
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 07 Feb 2002 Phase-II clinical trials for Psoriasis in USA (Topical)
  • 09 Nov 2001 A phase I trial in volunteers has been completed
  • 22 Jun 2001 Phase-I clinical trials for Skin disorders in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top